Ozkaya, MesutCakal, ErmanUstun, YusufEngin-Ustun, Yaprak2024-08-042024-08-0420100015-02821556-5653https://doi.org/10.1016/j.fertnstert.2008.10.058https://hdl.handle.net/11616/94966Objective: To evaluate serum visfatin levels and to determine the effects of metformin treatment on visfatin levels in patients with polycystic ovary syndrome (PCOS). Design: Cross-sectional study. Setting: University hospital. Patient(s): Nineteen patients with PCOS and 21 controls. Intervention(s): Metformin was given to patients with PCOS, and serum visfatin levels were measured before and after treatment. Main Outcome Measure(S): Glucose, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, DHEAS, total T, insulin, homeostatic model assessment for insulin resistance (HOMA-IR), and visfatin levels were measured. Result(s): Serum visfatin levels were significantly higher in women with PCOS than in controls. Visfatin could differentiate between women with and without increased diabetogenic risk at a cut-off value of 19.24 ng/mL, with a sensitivity of 93.3% and a specificity of 84%. In bivariate analysis of subjects, T, insulin, and waist circumference were significantly and positively correlated with visfatin. Treatment resulted in a significant decrease in body mass index and a decrease in visfatin concentration. After therapy, statistically significant decreases in HOMA-IR, fasting insulin, free T, and DHEAS concentrations were observed for the PCOS group. Conclusion(s): Circulating visfatin levels were higher in patients with PCOS than healthy controls, and metformin treatment significantly reduced circulating visfatin concentrations after 3 months of therapy. (Fertil Steril (R) 2010:93:880-4. (C)2010 by American Society for Reproductive Medicine.)eninfo:eu-repo/semantics/openAccessType-2 Diabetes-MellitusInsulin-ResistancePlasma VisfatinWomenHyperandrogenismGlucoseReleaseFatArticle9338808841911129810.1016/j.fertnstert.2008.10.0582-s2.0-75749115194Q1WOS:000274957300029Q1